Skip Navigation
Skip to contents

Cancer Res Treat : Cancer Research and Treatment

OPEN ACCESS

Search

Page Path
HOME > Search
1 "Soft tissue neoplasms"
Filter
Filter
Article category
Keywords
Publication year
Authors
Original Article
Extra-cranial Malignant Rhabdoid Tumor in Children: A Single Institute Experience
Che Ry Hong, Hyoung Jin Kang, Hee Young Ju, Ji Won Lee, Hyery Kim, Sung-Hye Park, Il Han Kim, Kyung Duk Park, Hee Young Shin
Cancer Res Treat. 2015;47(4):889-896.   Published online January 2, 2015
DOI: https://doi.org/10.4143/crt.2013.176
AbstractAbstract PDFPubReaderePub
Purpose
Malignant rhabdoid tumor (MRT) is a rare and highly aggressive tumor that affects young children. Due to its extreme rarity, most of the available data are based on retrospective case series. To add to the current knowledge of this disease, we reviewed the patients treated for extra-cranial MRT in our institute. Materials and Methods A retrospective medical record review was conducted on children treated for pathologically confirmed extra-cranial MRT at Seoul National University Children’s Hospital between January 2003 and May 2013. Results Eleven patients (7 boys, 4 girls) were diagnosed with extra-cranial MRT at a median age of 9 months old. INI1 staining was important in the pathological confirmation. Six patients (55%) had renal MRT and five (45%) had soft tissue MRT. Five patients (45%) had metastases at diagnosis. All patients underwent chemotherapy, eight patients (73%) underwent surgery, six patients (55%) received therapeutic radiotherapy, and four patients (36%) underwent high dose chemotherapy with autologous stem cell rescue (HDCT/ASCR) with melphalan, etoposide, and carboplatin. Five patients (45%) died of disease following progression (n=3) or relapse (n=2), however, there was no treatment related mortality. The overall survival of the cohort was 53.0% and the event-free survival was 54.5% with a median follow-up duration of 17.8 months (range, 2.3 to 112.3 months). Conclusion Extra-cranial MRT is still a highly aggressive tumor in young children. However, the improved survival of our cohort is promising and HDCT/ASCR with melphalan, etoposide, and carboplatin may be a promising treatment option.

Citations

Citations to this article as recorded by  
  • Extracranial malignant rhabdoid tumors in children: high mortality even with the help of an aggressive clinical approach
    Siqi Xie, Yuanyuan Fang, Yingying Yang, Lan Liu, Jianxi Bai, Sheng Lin, Bing Zhang, Yifan Fang
    European Journal of Pediatrics.2023; 183(2): 557.     CrossRef
  • Infantile Extracranial Rhabdoid Tumor of the Scalp
    Sura Al Rawabdeh, Deifallah Alsharari, Hayat Khasawneh, Ola M. Al Waqfi, Qamar Yaser Malabeh, Hiathem Abu Alhaija, Raed Mohammad Aljubour, Hamzeh M. Alkhawaldeh, Pablo Fernandez Pe as
    Case Reports in Medicine.2021; 2021: 1.     CrossRef
  • Pharmacokinetics of high-dose carboplatin in children undergoing high-dose chemotherapy and autologous stem cell transplantation with BSA-based dosing
    Che Ry Hong, Hyoung Jin Kang, Seol Ju Moon, Jaeseong Oh, Kyung Taek Hong, Jung Yoon Choi, Kyung-Sang Yu, Hee Young Shin
    Bone Marrow Transplantation.2020; 55(1): 137.     CrossRef
  • Successful Treatment of Extra‐Renal Noncerebral Rhabdoid Tumors with VIDE
    Naoko Yasui, Akihiko Yoshida, Eisuke Kobayashi, Fumihiko Nakatani, Hiroshi Kawamoto
    Pediatric Blood & Cancer.2016; 63(2): 352.     CrossRef
  • 14,592 View
  • 149 Download
  • 5 Web of Science
  • 4 Crossref
Close layer

Cancer Res Treat : Cancer Research and Treatment
Close layer
TOP